BiotechTube
SkyePharma

SkyePharma

Lyon, France· Est.
skyepharma.fr
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SkyePharma is a specialized French CDMO with over 25 years of experience, focusing on complex oral solid dosage forms, including multi-layer tablets, mini-tablets, and modified-release formulations. It has particular expertise in handling highly potent APIs (up to OEB 5), oncology drugs, controlled substances, and orphan drugs. The company operates a fully integrated, FDA and ANSM-approved facility, employs over 200 people, and serves a global client base, with about 40% of its customers in the US.

OncologyRare DiseasesVarious (CDMO)

Technology Platform

Proprietary oral solid dosage technologies including press-coated tablets, multi-layer tablets, gastro-retentive capsules, and specialized containment for HPAPI (OEB 4/5+) manufacturing. Utilizes Process Analytical Technology (PAT) and Quality by Design (QbD).

Opportunities

Growing demand for HPAPI manufacturing from the oncology sector and increased outsourcing of complex formulation work by biotechs and pharma.
The orphan drug market provides a strong niche for its small-batch agility.
Expansion into bioproduction support offers a new growth avenue.

Risk Factors

Dependence on client R&D budgets and outsourcing trends.
Regulatory and operational risk concentrated at its single integrated facility.
Competition from larger CDMOs and other niche players could pressure margins.

Competitive Landscape

SkyePharma competes in the specialized CDMO segment for complex oral solids and HPAPIs against other niche European players and larger global CDMOs. Its differentiation lies in its deep formulation expertise, proprietary technologies, and agile, integrated service model focused on highly challenging projects.

More companies in Small Molecule Drugs →More companies in France →